AVIR Strangle Strategy
AVIR (Atea Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR (Atea Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $404.9M, a beta of 0.27 versus the broader market, a 52-week range of 2.78-6.45, average daily share volume of 343K, a public-listing history dating back to 2020, approximately 55 full-time employees. These structural characteristics shape how AVIR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.27 indicates AVIR has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on AVIR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
AVIR snapshot
As of August 14, 2026, spot at $5.09, ATM IV 75.10%, IV rank 16.73%, expected move 21.53%. The strangle on AVIR below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on AVIR specifically: AVIR IV at 75.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a AVIR strangle, with a market-implied 1-standard-deviation move of approximately 21.53% (roughly $1.10 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AVIR expiries trade a higher absolute premium for lower per-day decay. Position sizing on AVIR should anchor to the underlying notional of $5.09 per share and to the trader's directional view on AVIR stock.
AVIR strangle setup
The AVIR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AVIR at $5.09 on that close, the first option leg uses a $5.34 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AVIR chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AVIR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.34 | N/A |
| Buy 1 | Put | $4.84 | N/A |
AVIR strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
AVIR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on AVIR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on AVIR
Strangles on AVIR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AVIR chain.
AVIR thesis for this strangle
The market-implied 1-standard-deviation range for AVIR extends from approximately $3.99 on the downside to $6.19 on the upside. A AVIR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current AVIR IV rank near 16.73% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AVIR at 75.10%. As a Healthcare name, AVIR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AVIR-specific events.
AVIR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AVIR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AVIR alongside the broader basket even when AVIR-specific fundamentals are unchanged. Always rebuild the position from current AVIR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on AVIR?
- A strangle on AVIR is the strangle strategy applied to AVIR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With AVIR stock at $5.09 on the most recent close, the strikes shown on this page are snapped to the nearest listed AVIR chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are AVIR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the AVIR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 75.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AVIR strangle?
- The breakeven for the AVIR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AVIR market-implied 1-standard-deviation expected move in the same options snapshot is approximately 21.53%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on AVIR?
- Strangles on AVIR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AVIR chain.
- How does current AVIR implied volatility affect this strangle?
- AVIR ATM IV is at 75.10% with IV rank near 16.73%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.